RightFit
RecruitingPhase not listed

Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid Leukemia

Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Patients With Chronic Myeloid Leukemia

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years and older
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

  • Procedures mentioned: Questionnaires, Interviews

Only what the study's summary and detailed description on ClinicalTrials.gov say. Time periods may describe the whole study or a part of it — ask the study team what applies to you.

Show the study's own words
  • "Consenting patients will participate in a focused interview where TKI adherence, personality type, and quality of life and symptom burden will be assessed using validated questionnaires."
Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This small study looks at whether personality is linked to how well people take their cancer medicine as prescribed. It is for adults with chronic myeloid leukemia (CML), a type of blood cancer, who take certain medicines called tyrosine kinase inhibitors.

This is an observational pilot study to examine the association between a patient's personality and adherence to tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • You are 18 or older.
  • You have CML in the chronic phase, when the cancer grows more slowly.
  • You currently take imatinib, dasatinib, bosutinib, or nilotinib.
  • You are a patient at the UCI Chao Family Comprehensive Cancer Center OR a member of a support group run by the CML Buster Foundation.
  • None of the exclusion rules apply to you.

Who can't join

  • You cannot read and speak English.
  • You have trouble understanding or making the decision to agree to join the study.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * 18 years of age or older * Diagnosed with chronic myeloid leukemia (CML) and in the chronic phase (CML-CP) * Currently being treated with one of four cancer medications - imatinib, dasatinib, bosutinib, or nilotinib * A patient at the UCI Chao Family Comprehensive Cancer Center (CFCCC), or * A member of a patient support group organized by the CML Buster Foundation * Do not meet any of the criteria listed under "Exclusion Requirements" Exclusion Criteria: * Unable to read and speak English * Impaired decisional capacity to consent

Study sites (1)

CA